Aarti Pharmalabs Ltd
Aarti Pharmalabs Ltd (AARTIPHARM) is scheduled to report results on 28 Oct 2026. Aarti Pharmalabs Ltd last reported results for the quarter ended Jun 2026, with sales of ₹536 crore and net profit of ₹76 crore. The stock last traded at ₹978, a market capitalisation of ₹8,872 crore, on a P/E of 41.2. Over the past 52 weeks the stock has ranged between ₹584 and ₹1,002. Figures are as of 6 Oct 2026 and are not real time.
Aarti Pharmalabs Ltd share price and key metrics
- Current price
- ₹978
- Market cap
- ₹8,872 cr
- Stock P/E
- 41.2
- Book value
- ₹234
- ROE
- 8.59%
- ROCE
- 10.7%
- Dividend yield
- 0.37%
- 52w high / low
- 1002/584
Metrics as of 6 Oct 2026. Not real time.
Track Aarti Pharmalabs Ltd
Cruxal reads every Aarti Pharmalabs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Aarti Pharmalabs Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -2%
- TTM
- 1%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -3%
- TTM
- -19%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 31%
- 1 Year
- 14%
- 10 Years
- %
- 5 Years
- 13%
- 3 Years
- 12%
- Last Year
- 9%
Aarti Pharmalabs Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹536 cr, up 38.9% from ₹386 cr a year earlier. Net profit was ₹76 cr, up 52.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 458 | 538 | 564 | 386 | 418 | 432 | 583 | 536 |
| Expenses | 364 | 409 | 418 | 293 | 344 | 330 | 470 | 400 |
| Operating profit | 94 | 129 | 146 | 93 | 74 | 102 | 113 | 136 |
| OPM % | 20% | 24% | 26% | 24% | 18% | 24% | 19% | 25% |
| Other income | 4 | 5 | -2 | 2 | 0 | 2 | 14 | 8 |
| Interest | 6 | 10 | 7 | 7 | 11 | 13 | 17 | 13 |
| Depreciation | 21 | 23 | 23 | 23 | 25 | 29 | 28 | 30 |
| Profit before tax | 72 | 101 | 115 | 65 | 39 | 63 | 82 | 101 |
| Tax % | 24% | 26% | 23% | 24% | 28% | 24% | 25% | 25% |
| Net profit | 55 | 74 | 88 | 50 | 28 | 48 | 61 | 76 |
| EPS (₹) | 6.03 | 8.16 | 9.75 | 5.46 | 3.08 | 5.29 | 6.74 | 8.40 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Aarti Pharmalabs Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 0 | 1,200 | 1,945 | 1,853 | 2,115 | 1,819 | 1,969 |
| Operating profit | 0 | 207 | 342 | 386 | 466 | 369 | 426 |
| OPM % | — | 17% | 18% | 21% | 22% | 20% | 22% |
| Net profit | 0 | 122 | 193 | 217 | 272 | 175 | 213 |
| EPS (₹) | — | — | 21.35 | 23.93 | 30.05 | 19.27 | 23.51 |
TTM is the trailing twelve months to the most recent quarter.
Aarti Pharmalabs Ltd balance sheet
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 0.25 | 0.25 | 45 | 45 | 45 | 45 |
| Reserves | -0 | 1,386 | 1,513 | 1,712 | 1,945 | 2,079 |
| Borrowings | 0 | 338 | 215 | 285 | 413 | 754 |
| Other liabilities | 0 | 315 | 470 | 540 | 499 | 603 |
| Total liabilities | 0 | 2,040 | 2,244 | 2,582 | 2,902 | 3,482 |
| Fixed assets | 0 | 782 | 926 | 1,033 | 1,137 | 1,437 |
| CWIP | 0 | 187 | 102 | 137 | 374 | 393 |
| Investments | 0 | 32 | 87 | 107 | 77 | 194 |
| Other assets | 0 | 1,038 | 1,130 | 1,305 | 1,315 | 1,457 |
| Total assets | 0 | 2,040 | 2,244 | 2,582 | 2,902 | 3,482 |
As reported by the company. Total assets equal total liabilities by construction.
Aarti Pharmalabs Ltd cash flow
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 0 | -44 | 250 | 216 | 330 | 262 |
| Cash from investing | 0 | -139 | -158 | -215 | -412 | -431 |
| Cash from financing | 0 | 260 | -163 | 10 | 65 | 171 |
| Net cash flow | 0 | 78 | -71 | 12 | -17 | 2 |
| Free cash flow | 0 | -185 | 130 | 18 | -114 | -186 |
| CFO / operating profit | — | -11% | 91% | 71% | 85% | 84% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Aarti Pharmalabs Ltd operating ratios
| Per year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROCE % | 19% | 16% | 17% | 17% | 11% |
| Debtor days | 115 | 84 | 102 | 99 | 117 |
| Inventory days | 272 | 188 | 230 | 199 | 280 |
| Days payable | 123 | 106 | 135 | 94 | 146 |
| Cash conversion cycle | 264 | 166 | 197 | 204 | 251 |
| Working capital days | 111 | 94 | 110 | 105 | 90 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Aarti Pharmalabs Ltd shareholding pattern
Promoters held 42.86% at Jun 2026, down from 43.72% at Jun 2025. FIIs 8.17% and DIIs 7.22%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 46.10% | 44.65% | 44.29% | 43.72% | 42.88% | 43.10% | 43.08% | 42.86% |
| FIIs | 7.38% | 8.64% | 7.36% | 7.34% | 8.02% | 7.69% | 8.39% | 8.17% |
| DIIs | 11.35% | 10.36% | 7.53% | 7.80% | 6.95% | 7.66% | 7.40% | 7.22% |
| Government | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 35.17% | 36.33% | 40.81% | 41.12% | 42.12% | 41.54% | 41.10% | 41.74% |
| No. of shareholders | 1,85,436 | 1,85,111 | 1,96,314 | 1,87,039 | 1,90,655 | 1,84,489 | 1,79,373 | 1,76,506 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Aarti Pharmalabs Ltd’s next results date?
Aarti Pharmalabs Ltd’s next results are scheduled for 28 Oct 2026.
- Board meetingApproval of unaudited financial results for Q2 and H1 FY2027
See the full results calendar for every Indian company reporting in the next 30 days.
Cruxal coverage of Aarti Pharmalabs Ltd
Aarti Pharmalabs Ltd corporate filings
- Board Meeting Scheduled to Approve September 2026 Quarter Results; No Financial Data DisclosedBoard Meetinglow impact
Cruxal's analysis: Aarti Pharmalabs Limited has announced a board meeting scheduled for October 28, 2026, to…
Read the full analysis - Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, for the quarter ended September 30, 2026.Company Updatelow impact
- Aarti Pharmalabs Ltd files regulatory intimation; no financial or operational changes disclosedCompany Updatelow impact
Cruxal's analysis: The company has submitted an intimation under SEBI Regulation 30 on September 30, 2026…
Read the full analysis - Aarti Pharmalabs Intimates Filing Under Regulation 30 of SEBI Listing RegulationsCompany Updatelow impact
Cruxal's analysis: The company, with a market cap of approximately 8825.87 crore and current stock price of…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
- Aarti Pharmalabs Announces Leadership Transition: Rashesh C. Gogri Appointed Managing DirectorCompany Updatelow impact
Cruxal's analysis: Aarti Pharmalabs Limited has announced a key leadership transition effective October 1…
Read the full analysis - Aarti Pharmalabs Limited Announces AGM Voting Results and Leadership TransitionAGM/EGMmedium impact
Cruxal's analysis: Aarti Pharmalabs Limited has successfully concluded its 7th Annual General Meeting, with…
Read the full analysis - Aarti Pharmalabs Limited: Promoter Group Reports Net Stake Reduction of 3.20% via Open/Off-Market TransactionsInsider Trading / SASTmedium impact
Cruxal's analysis: Aarti Pharmalabs Limited has disclosed a change in promoter shareholding where the…
Read the full analysis - Aarti Pharmalabs Limited Investor Presentation Highlights FY26 Financial Performance and Future Growth StrategyCompany Updatemedium impact
Cruxal's analysis: Aarti Pharmalabs Limited released its investor presentation following its 7th Annual…
Read the full analysis - Aarti Pharmalabs Limited Announces 7th AGM Proceedings and Leadership RestructuringAGM/EGMlow impact
Cruxal's analysis: Aarti Pharmalabs Limited successfully concluded its 7th Annual General Meeting, where…
Read the full analysis - Aarti Pharmalabs Ltd: Routine Regulatory Filing Under SEBI LODRCompany Updatelow impact
Cruxal's analysis: Aarti Pharmalabs Ltd has submitted a routine intimation under Regulation 30 of the SEBI…
Read the full analysis - Aarti Pharmalabs Limited announces resignation of Senior Management PersonnelCompany Updatelow impact
Cruxal's analysis: Aarti Pharmalabs Limited has formally announced the resignation of Shri G.M. Naidu, who…
Read the full analysis - Aarti Pharmalabs Ltd: Routine Newspaper Publication of Financial ResultsCompany Updatelow impact
Cruxal's analysis: Aarti Pharmalabs Ltd has fulfilled its regulatory obligation under Regulation 30 of the…
Read the full analysis - Aarti Pharmalabs Ltd files Business Responsibility and Sustainability Report (BRSR) for FY 2025-26Otherslow impact
Cruxal's analysis: Aarti Pharmalabs Ltd has submitted its Business Responsibility and Sustainability Report…
Read the full analysis - Aarti Pharmalabs Limited Announces 7th AGM and Releases Annual Report for FY 2025-26AGM/EGMmedium impact
Cruxal's analysis: Aarti Pharmalabs Limited has issued the notice for its 7th Annual General Meeting (AGM)…
Read the full analysis - Aarti Pharmalabs Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Aarti Pharmalabs Ltd has filed its Annual Report for the financial year 2025-26 as per…
Read the full analysis - Aarti Pharmalabs Ltd files routine newspaper publication regarding regulatory complianceCompany Updatelow impact
Cruxal's analysis: Aarti Pharmalabs Ltd has submitted a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - Aarti Pharmalabs Limited fixes September 15, 2026 as Record Date for final dividend of INR 2.00 per shareCorp. Actionlow impact
Cruxal's analysis: Aarti Pharmalabs Limited has officially announced Tuesday, September 15, 2026, as the…
Read the full analysis - Aarti Pharmalabs Q1 FY27 Earnings: Strong 42% YoY Revenue Growth Driven by Xanthine Derivatives; Management Reaffirms Long-term CDMO Growth TargetsCompany Updatehigh impact
Cruxal's analysis: Aarti Pharmalabs reported strong Q1 FY27 standalone revenue of INR 535 crore, a 42% YoY…
Read the full analysis - Aarti Pharmalabs Ltd releases audio recording of investor and analyst conference callCompany Updatelow impact
Cruxal's analysis: Aarti Pharmalabs Ltd has filed the audio recording of its conference call held with…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.